Global Cancer Biomarker Market
Industry Size, Competitive Landscape, Segmentation & Forecast (2026–2036)
Market Overview
The global Cancer Biomarker market represents a cornerstone of modern oncology, enabling early cancer detection, prognosis assessment, therapy selection, treatment monitoring, and personalized medicine. Cancer biomarkers include genetic, epigenetic, proteomic, and metabolic indicators used extensively in diagnostics, drug discovery, and clinical decision-making.
In 2017, the global Cancer Biomarker market was valued at XX million US$ and is expected to reach XX million US$ by 2036, registering a CAGR of XX% during 2026–2036. Market expansion is driven by the rising global cancer burden, advances in molecular diagnostics, growth in precision medicine, and increasing adoption of companion diagnostics in oncology therapeutics.
Competitive Landscape – Key Market Players
The market is highly competitive and innovation-driven, dominated by multinational life-science companies, diagnostics leaders, and genomics specialists focusing on next-generation sequencing (NGS), liquid biopsy, and multi-omics platforms.
Major Companies Profiled
-
Abbott Laboratories
-
F. Hoffmann-La Roche Ltd.
-
QIAGEN
-
Thermo Fisher Scientific
-
Affymetrix
-
Illumina
-
Agilent Technologies
-
Merck & Co.
-
Hologic
-
Sino Biological
-
Becton Dickinson
Additional Active & Emerging Players
-
Bio-Rad Laboratories
-
Guardant Health
-
Exact Sciences
-
Roche Diagnostics
-
Amgen (biomarker-driven oncology pipeline)
-
Sysmex Corporation
Segmentation Analysis
By Biomarker Type
-
Genetic Biomarkers
-
Epigenetic Biomarkers
-
Proteomic Biomarkers
-
Metabolic Biomarkers
-
Cell-based & Circulating Biomarkers (CTCs, cfDNA)
Insight: Genetic and epigenetic biomarkers dominate due to widespread adoption of NGS and liquid biopsy technologies.
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Prostate Cancer
-
Hematological Malignancies
-
Other Solid Tumors
By Application
-
Drug Discovery & Development
-
Diagnostics & Screening
-
Personalized & Precision Medicine
-
Prognostic & Predictive Testing
-
Other Research Applications
Insight: Diagnostics and personalized medicine represent the fastest-growing application segments.
By End User
-
Hospitals & Diagnostic Laboratories
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutes
-
Contract Research Organizations (CROs)
Regional Analysis
North America
-
Largest market due to advanced healthcare infrastructure and strong oncology R&D.
-
The United States leads in biomarker-driven drug approvals.
Europe
-
Strong regulatory support for companion diagnostics.
-
Germany, the UK, and France are major contributors.
Asia-Pacific
-
Fastest-growing region due to rising cancer incidence and improving diagnostic access.
-
China, Japan, and India drive regional demand.
Central & South America
-
Moderate growth supported by improving cancer screening programs.
Middle East & Africa
-
Emerging market with increasing investment in oncology diagnostics.
Porter’s Five Forces Analysis
-
Threat of New Entrants: Moderate – High R&D and regulatory barriers
-
Bargaining Power of Suppliers: Moderate – Specialized reagents and platforms
-
Bargaining Power of Buyers: High – Hospitals and pharma companies negotiate pricing
-
Threat of Substitutes: Low – Biomarkers are integral to precision oncology
-
Competitive Rivalry: High – Rapid innovation and patent competition
SWOT Analysis
Strengths
-
Strong clinical relevance in oncology
-
Technological advances in genomics and proteomics
-
Integration with targeted therapies
Weaknesses
-
High development and validation costs
-
Complex regulatory approval pathways
Opportunities
-
Expansion of liquid biopsy applications
-
Growth in AI-enabled biomarker discovery
-
Increasing demand in emerging markets
Threats
-
Data privacy and regulatory challenges
-
Rapid technological obsolescence
-
Reimbursement uncertainties
Market Trends
-
Rapid adoption of liquid biopsy and non-invasive biomarkers
-
Integration of AI and bioinformatics in biomarker discovery
-
Growing emphasis on companion diagnostics
-
Expansion of multi-omics and personalized oncology platforms
Market Drivers & Challenges
Key Drivers
-
Rising global cancer prevalence
-
Shift toward precision and personalized medicine
-
Increased oncology drug development activity
Key Challenges
-
High cost of biomarker development
-
Regulatory and reimbursement complexity
-
Standardization and validation issues
Value Chain Analysis
-
Biomarker Discovery & Identification
-
Assay Development & Validation
-
Clinical Trials & Regulatory Approval
-
Manufacturing & Quality Control
-
Distribution & Commercialization
-
Clinical & Research End Use
Strategic Recommendations for Stakeholders
-
Diagnostic Companies: Invest in liquid biopsy and multi-omics platforms
-
Pharma Companies: Strengthen companion diagnostic collaborations
-
Hospitals: Expand molecular diagnostic capabilities
-
Investors: Target AI-driven and precision oncology players
-
Policy Makers: Support biomarker reimbursement frameworks
Study Timeline
-
Historical Period: 2020–2024
-
Base Year: 2025
-
Estimated Year: 2026
-
Forecast Period: 2026–2036
Key Stakeholders
-
Cancer Biomarker Manufacturers
-
Diagnostic Laboratories
-
Pharmaceutical & Biotechnology Companies
-
Research Institutes & CROs
-
Regulatory & Healthcare Authorities
Customization Options Available
-
Country-level market forecasts
-
Cancer-specific biomarker analysis
-
Liquid biopsy vs tissue-based comparison
-
Competitive benchmarking of additional players
Table of Contents
Global Cancer Biomarker global market
1 Industry Overview of Cancer Biomarker
1.1 Cancer Biomarker Market Overview
1.1.1 Cancer Biomarker Product Scope
1.1.2 Market Status and Outlook
1.2 Global Cancer Biomarker Market Size and Analysis by Regions ()
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Cancer Biomarker Market by Type
1.3.1 Genetic Biomarkers
1.3.2 Epigenetic Biomarkers
1.3.3 Metabolic Biomarkers
1.3.4 Proteomic Biomarkers
1.3.5 Others
1.4 Cancer Biomarker Market by End Users/Application
1.4.1 Drug discovery and Development
1.4.2 Diagnostics
1.4.3 Personalized medicine
1.4.4 Others
2 Global Cancer Biomarker Competition Analysis by Players
2.1 Cancer Biomarker Market Size (Value) by Players ()
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Abbott Laboratories
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Cancer Biomarker Revenue (Million USD) ()
3.2 F.Hoffmann-La Roche Ltd.
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Cancer Biomarker Revenue (Million USD) ()
3.3 QIAGEN
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Cancer Biomarker Revenue (Million USD) ()
3.4 Thermo Fisher Scientific Inc.
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Cancer Biomarker Revenue (Million USD) ()
3.5 Affymetrix Inc.
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Cancer Biomarker Revenue (Million USD) ()
3.6 Illumina, Inc.
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Cancer Biomarker Revenue (Million USD) ()
3.7 Agilent Technologies
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Cancer Biomarker Revenue (Million USD) ()
3.8 Merck & Co. Inc.
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Cancer Biomarker Revenue (Million USD) ()
3.9 Hologic, Inc.
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Cancer Biomarker Revenue (Million USD) ()
3.10 Sino Biological Inc.
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Cancer Biomarker Revenue (Million USD) ()
3.11 Becton, Dickinson and Company
4 Global Cancer Biomarker Market Size by Type and Application ()
4.1 Global Cancer Biomarker Market Size by Type ()
4.2 Global Cancer Biomarker Market Size by Application ()
4.3 Potential Application of Cancer Biomarker in Future
4.4 Top Consumer/End Users of Cancer Biomarker
5 United States Cancer Biomarker Development Status and Outlook
5.1 United States Cancer Biomarker Market Size ()
5.2 United States Cancer Biomarker Market Size and Market Share by Players ()
5.3 United States Cancer Biomarker Market Size by Application ()
6 Europe Cancer Biomarker Development Status and Outlook
6.1 Europe Cancer Biomarker Market Size ()
6.2 Europe Cancer Biomarker Market Size and Market Share by Players ()
6.3 Europe Cancer Biomarker Market Size by Application ()
7 China Cancer Biomarker Development Status and Outlook
7.1 China Cancer Biomarker Market Size ()
7.2 China Cancer Biomarker Market Size and Market Share by Players ()
7.3 China Cancer Biomarker Market Size by Application ()
8 Japan Cancer Biomarker Development Status and Outlook
8.1 Japan Cancer Biomarker Market Size ()
8.2 Japan Cancer Biomarker Market Size and Market Share by Players ()
8.3 Japan Cancer Biomarker Market Size by Application ()
9 Southeast Asia Cancer Biomarker Development Status and Outlook
9.1 Southeast Asia Cancer Biomarker Market Size ()
9.2 Southeast Asia Cancer Biomarker Market Size and Market Share by Players ()
9.3 Southeast Asia Cancer Biomarker Market Size by Application ()
10 India Cancer Biomarker Development Status and Outlook
10.1 India Cancer Biomarker Market Size ()
10.2 India Cancer Biomarker Market Size and Market Share by Players ()
10.3 India Cancer Biomarker Market Size by Application ()
11 Market Forecast by Regions, Type and Application ()
11.1 Global Cancer Biomarker Market Size (Value) by Regions ()
11.1.1 United States Cancer Biomarker Revenue and Growth Rate ()
11.1.2 Europe Cancer Biomarker Revenue and Growth Rate ()
11.1.3 China Cancer Biomarker Revenue and Growth Rate ()
11.1.4 Japan Cancer Biomarker Revenue and Growth Rate ()
11.1.5 Southeast Asia Cancer Biomarker Revenue and Growth Rate ()
11.1.6 India Cancer Biomarker Revenue and Growth Rate ()
11.2 Global Cancer Biomarker Market Size (Value) by Type ()
11.3 Global Cancer Biomarker Market Size by Application ()
12 Cancer Biomarker Market Dynamics
12.1 Cancer Biomarker Market Opportunities
12.2 Cancer Biomarker Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Cancer Biomarker Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Cancer Biomarker Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Global Cancer Biomarker Market Size (Million USD) Status and Outlook ()
Table Global Cancer Biomarker Revenue (Million USD) Comparison by Regions ()
Figure Global Cancer Biomarker Market Share by Regions ()
Figure United States Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Figure Europe Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Figure China Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Figure Japan Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Figure Southeast Asia Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Figure India Cancer Biomarker Market Size (Million USD) and Growth Rate by Regions ()
Table Global Cancer Biomarker Revenue (Million USD) and Growth Rate (%) Comparison by Product ()
Figure Global Cancer Biomarker Revenue Market Share by Type in 2017
Figure Genetic Biomarkers Market Size (Million USD) and Growth Rate ()
Figure Epigenetic Biomarkers Market Size (Million USD) and Growth Rate ()
Figure Metabolic Biomarkers Market Size (Million USD) and Growth Rate ()
Figure Proteomic Biomarkers Market Size (Million USD) and Growth Rate ()
Figure Others Market Size (Million USD) and Growth Rate ()
Figure Global Cancer Biomarker Market Share by Application in 2017
Figure Cancer Biomarker Market Size (Million USD) and Growth Rate in Drug discovery and Development ()
Figure Cancer Biomarker Market Size (Million USD) and Growth Rate in Diagnostics ()
Figure Cancer Biomarker Market Size (Million USD) and Growth Rate in Personalized medicine ()
Figure Cancer Biomarker Market Size (Million USD) and Growth Rate in Others ()
Table Cancer Biomarker Market Size (Million USD) by Players ()
Figure Cancer Biomarker Market Size Share by Players in 2013
Figure Cancer Biomarker Market Size Share by Players in 2017
Table Abbott Laboratories Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Abbott Laboratories ()
Figure Abbott Laboratories Cancer Biomarker Business Revenue Market Share ()
Table F.Hoffmann-La Roche Ltd. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of F.Hoffmann-La Roche Ltd. ()
Figure F.Hoffmann-La Roche Ltd. Cancer Biomarker Business Revenue Market Share ()
Table QIAGEN Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of QIAGEN ()
Figure QIAGEN Cancer Biomarker Business Revenue Market Share ()
Table Thermo Fisher Scientific Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Thermo Fisher Scientific Inc. ()
Figure Thermo Fisher Scientific Inc. Cancer Biomarker Business Revenue Market Share ()
Table Affymetrix Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Affymetrix Inc. ()
Figure Affymetrix Inc. Cancer Biomarker Business Revenue Market Share ()
Table Illumina, Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Illumina, Inc. ()
Figure Illumina, Inc. Cancer Biomarker Business Revenue Market Share ()
Table Agilent Technologies Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Agilent Technologies ()
Figure Agilent Technologies Cancer Biomarker Business Revenue Market Share ()
Table Merck & Co. Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Merck & Co. Inc. ()
Figure Merck & Co. Inc. Cancer Biomarker Business Revenue Market Share ()
Table Hologic, Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Hologic, Inc. ()
Figure Hologic, Inc. Cancer Biomarker Business Revenue Market Share ()
Table Sino Biological Inc. Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Sino Biological Inc. ()
Figure Sino Biological Inc. Cancer Biomarker Business Revenue Market Share ()
Table Becton, Dickinson and Company Basic Information List
Table Cancer Biomarker Business Revenue (Million USD) of Becton, Dickinson and Company ()
Figure Becton, Dickinson and Company Cancer Biomarker Business Revenue Market Share ()
Table Global Cancer Biomarker Market Size (Million USD) by Product ()
Figure Global Cancer Biomarker Revenue Market Share (%) by Product ()
Figure Global Cancer Biomarker Market Share by Product in 2017
Table Global Cancer Biomarker Market Size by Application ()
Figure Global Cancer Biomarker Revenue Market Share (%) by Application in 2017
Table Top Consumer/End Users of Cancer Biomarker
Figure United States Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table United States Cancer Biomarker Market Size (Million USD) by Players ()
Figure United States Cancer Biomarker Market Size Share by Players in 2013
Figure United States Cancer Biomarker Market Size Share by Players in 2017
Table United States Cancer Biomarker Market Size by Application ()
Figure United States Cancer Biomarker Revenue Market Share (%) by Application ()
Figure United States Cancer Biomarker Market Size Share by Application in 2017
Figure Europe Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table Europe Cancer Biomarker Market Size (Million USD) by Players ()
Figure Europe Cancer Biomarker Market Size Share by Players in 2013
Figure Europe Cancer Biomarker Market Size Share by Players in 2017
Table Europe Cancer Biomarker Market Size by Application ()
Figure Europe Cancer Biomarker Revenue Market Share (%) by Application ()
Figure Europe Cancer Biomarker Market Size Share by Application in 2017
Figure China Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table China Cancer Biomarker Market Size (Million USD) by Players ()
Figure China Cancer Biomarker Market Size Share by Players in 2013
Figure China Cancer Biomarker Market Size Share by Players in 2017
Table China Cancer Biomarker Market Size by Application ()
Figure China Cancer Biomarker Revenue Market Share (%) by Application ()
Figure China Cancer Biomarker Market Size Share by Application in 2017
Figure Japan Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table Japan Cancer Biomarker Market Size (Million USD) by Players ()
Figure Japan Cancer Biomarker Market Size Share by Players in 2013
Figure Japan Cancer Biomarker Market Size Share by Players in 2017
Table Japan Cancer Biomarker Market Size by Application ()
Figure Japan Cancer Biomarker Revenue Market Share (%) by Application ()
Figure Japan Cancer Biomarker Market Size Share by Application in 2017
Figure Southeast Asia Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table Southeast Asia Cancer Biomarker Market Size (Million USD) by Players ()
Figure Southeast Asia Cancer Biomarker Market Size Share by Players in 2013
Figure Southeast Asia Cancer Biomarker Market Size Share by Players in 2017
Table Southeast Asia Cancer Biomarker Market Size by Application ()
Figure Southeast Asia Cancer Biomarker Revenue Market Share (%) by Application ()
Figure Southeast Asia Cancer Biomarker Market Size Share by Application in 2017
Figure India Cancer Biomarker Market Size (Million USD) and Growth Rate ()
Table India Cancer Biomarker Market Size (Million USD) by Players ()
Figure India Cancer Biomarker Market Size Share by Players in 2013
Figure India Cancer Biomarker Market Size Share by Players in 2017
Table India Cancer Biomarker Market Size by Application ()
Figure India Cancer Biomarker Revenue Market Share (%) by Application ()
Figure India Cancer Biomarker Market Size Share by Application in 2017
Figure Global Cancer Biomarker Market Size and Growth Rate ()
Table Global Cancer Biomarker Market Size (Million USD) by Regions ()
Figure Global Cancer Biomarker Market Size Share ()
Figure Global Cancer Biomarker Market Size Share by Regions in 2025
Figure United States Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Figure Europe Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Figure China Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Figure Japan Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Figure Southeast Asia Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Figure India Cancer Biomarker Revenue (Million USD) and Growth Rate ()
Table Global Cancer Biomarker Market Size (Million USD) by Type ()
Figure Global Cancer Biomarker Market Size Share by Type in 2018
Figure Global Cancer Biomarker Market Size Share by Type in 2025
Table Global Cancer Biomarker Market Size (Million USD) by Application ()
Figure Global Cancer Biomarker Market Size (Million USD) by Application in 2018
Competitive Landscape – Key Market Players
The market is highly competitive and innovation-driven, dominated by multinational life-science companies, diagnostics leaders, and genomics specialists focusing on next-generation sequencing (NGS), liquid biopsy, and multi-omics platforms.
Major Companies Profiled
-
Abbott Laboratories
-
F. Hoffmann-La Roche Ltd.
-
QIAGEN
-
Thermo Fisher Scientific
-
Affymetrix
-
Illumina
-
Agilent Technologies
-
Merck & Co.
-
Hologic
-
Sino Biological
-
Becton Dickinson
Additional Active & Emerging Players
-
Bio-Rad Laboratories
-
Guardant Health
-
Exact Sciences
-
Roche Diagnostics
-
Amgen (biomarker-driven oncology pipeline)
-
Sysmex Corporation
Segmentation Analysis
By Biomarker Type
-
Genetic Biomarkers
-
Epigenetic Biomarkers
-
Proteomic Biomarkers
-
Metabolic Biomarkers
-
Cell-based & Circulating Biomarkers (CTCs, cfDNA)
Insight: Genetic and epigenetic biomarkers dominate due to widespread adoption of NGS and liquid biopsy technologies.
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Prostate Cancer
-
Hematological Malignancies
-
Other Solid Tumors
By Application
-
Drug Discovery & Development
-
Diagnostics & Screening
-
Personalized & Precision Medicine
-
Prognostic & Predictive Testing
-
Other Research Applications
Insight: Diagnostics and personalized medicine represent the fastest-growing application segments.
By End User
-
Hospitals & Diagnostic Laboratories
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutes
-
Contract Research Organizations (CROs)
